Resultados da busca - Gil Awada

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition por Gil Awada, Teofila Seremet, Karel Fostier, Hendrik Everaert, Bart Neyns

Obter o texto integral

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome por Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns, Hendrik Everaert

Obter o texto integral

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report por Ine Lambert, Giuseppe Fasolino, Gil Awada, Robert Kuijpers, Marcel ten Tusscher, Bart Neyns

Obter o texto integral

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report por Iris Dirven, Evan Calliauw, Gil Awada, Manon Vounckx, Jolien I. Kessels, Bart Neyns

Obter o texto integral

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1 por Gil Awada, Daphne Serruys, Julia Katharina Schwarze, Lien Van De Voorde, Johnny Duerinck, Bart Neyns

Obter o texto integral

Intratumoral Combinatorial Administration of CD1c (BDCA-1)⁺ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Pa... por Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

Obter o texto integral

COVID-19 and Cushing’s disease in a patient with ACTH-secreting pituitary carcinoma por J M K de Filette, Bastiaan Sol, Gil Awada, Corina E Andreescu, David Unuane, Sandrine Aspeslagh, Jan Poelaert, Bert Bravenboer

Obter o texto integral

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory adva... por Bart Neyns, Angela Vasaturo, Julia Katharina Schwarze, Gil Awada, Ramses Forsyth, Jens Tijtgat, Louise Cras, Christopher Bagnall, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet

Obter o texto integral

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab por Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, Jan L. Bernheim, Bart Neyns

Obter o texto integral

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy por Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, Mélanie Delaunoy, Hakim El Housni, Gil Awada, Julia Katharina Schwarze, Marleen Keyaerts, Hendrik Everaert, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns

Obter o texto integral

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx) por Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laila Ben Salama, Jennifer De Cremer, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck

Obter o texto integral

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial por Mark Kockx, Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laura Seynaeve, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Johnny Duerinck, Ramses Forsyth, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Louise Cras, Nicky D’Haene, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Sonia Van Dooren

Obter o texto integral